These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1773 related articles for article (PubMed ID: 15748904)

  • 61. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.
    Wang Z; Zhang L; Yeung TK; Chen X
    Mol Biol Cell; 1999 May; 10(5):1621-36. PubMed ID: 10233167
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells.
    Nam JM; Jeon KH; Kwon H; Lee E; Jun KY; Jin YB; Lee YS; Na Y; Kwon Y
    Eur J Pharm Sci; 2013 Oct; 50(2):181-90. PubMed ID: 23835029
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
    Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
    J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
    Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
    Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
    Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
    Henson ES; Hu X; Gibson SB
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
    Mayordomo C; García-Recio S; Ametller E; Fernández-Nogueira P; Pastor-Arroyo EM; Vinyals L; Casas I; Gascón P; Almendro V
    J Cell Physiol; 2012 Apr; 227(4):1358-66. PubMed ID: 21604273
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A; De Luca A; Maiello MR; Lamura L; Rachiglio AM; Napolitano M; Gallo M; Normanno N
    Breast Cancer Res Treat; 2010 Sep; 123(2):387-96. PubMed ID: 19946741
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol.
    Miyagawa S; Katsu Y; Watanabe H; Iguchi T
    Oncogene; 2004 Jan; 23(2):340-9. PubMed ID: 14647453
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. New insights into anti-HER-2 receptor monoclonal antibody research.
    Kumar R; Mandal M; Vadlamudi R
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [188Re-labeled herceptin inhibits proliferation of breast cancer cell line SKBR-3 in vitro].
    Li GP; Zhang YF; Wang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1455-7. PubMed ID: 17062351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.